alendronate has been researched along with Sarcopenia in 2 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Sarcopenia: Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alendronate is a widely used drug for osteoporosis in the elderly and postmenopausal women." | 5.48 | Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation. ( Chan, DC; Chiang, CK; Chiu, CY; Chiu, HC; Liu, SH; Yang, RS, 2018) |
| "The aims of this study were to assess changes in muscle mass and strength according to changes in bone mineral density (BMD) after alendronate-calcitriol therapy and to assess subsequent changes in common biomarkers for osteoporosis and sarcopenia to establish a common strategy against these coexisting conditions." | 3.79 | Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women. ( Cho, S; Choi, YS; Lee, BS; Park, HS; Park, JH; Park, KH; Seo, SK, 2013) |
| "Alendronate is a widely used drug for osteoporosis in the elderly and postmenopausal women." | 1.48 | Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation. ( Chan, DC; Chiang, CK; Chiu, CY; Chiu, HC; Liu, SH; Yang, RS, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiu, HC | 1 |
| Chiu, CY | 1 |
| Yang, RS | 1 |
| Chan, DC | 1 |
| Liu, SH | 1 |
| Chiang, CK | 1 |
| Park, JH | 1 |
| Park, KH | 1 |
| Cho, S | 1 |
| Choi, YS | 1 |
| Seo, SK | 1 |
| Lee, BS | 1 |
| Park, HS | 1 |
2 other studies available for alendronate and Sarcopenia
| Article | Year |
|---|---|
Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Animals; Bone Density Conservation Agents; Cells, Cultu | 2018 |
Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcitriol; Drug Therapy, Combination; | 2013 |